Retrospective Evaluation of the Effectiveness of Oral Pentosan Polysulfate Treatment in the Improvement of Chronic Interstitial Cystitis Symptoms
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 37
- Locations
- 2
- Primary Endpoint
- improvement of lower urinary tract symptoms
Study Overview
Brief Summary
To examine the relationship between symptoms and quality of life before and after oral pentosan polysulfate (PPS) treatment in cases diagnosed with interstitial cystitis/painful bladder syndrome (IC/BPS).
Detailed Description
Demographic characteristics, medical history, clinical conditions, and laboratory and cystoscopic data of patients who applied to our clinic between January 2018 and December 2021 and were diagnosed with IC/BPS were retrospectively analyzed. Adult male and female patients with IC/BPS who received 300 mg/day PPS at least six months ago with complaints of pain, urge, frequency, and nocturia not associated with urinary tract infection were included in the study. In addition, pre- and post-treatment symptoms, ICSI scores, quality of life (scored between 1-4), and satisfaction were compared.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Sequential
- Primary Purpose
- Treatment
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Chronic interstitial cystitis
- •Bladder Pain Syndrome
Exclusion Criteria
- •Acute cystitis
- •Bladder cancer
- •Chronic prostatitis
- •Bladder stone
- •Stress incontinence
Arms & Interventions
With Hunner's ulcer
Pentosan Polysulfate 100 mg
Intervention: Pentosan Polysulphate (Other)
Without Hunner's ulcer
Pentosan Polysulfate 100 mg
Intervention: Pentosan Polysulphate (Other)
Outcomes
Primary Outcomes
improvement of lower urinary tract symptoms
Time Frame: Three months
1 if symptoms improved, 0 if not
bladder wall thickness
Time Frame: Three months
0.3 over 3 mm 1 under 3 mm,
Secondary Outcomes
No secondary outcomes reported
Investigators
Basri Cakiroglu
Principal Investigator
Hisar Intercontinental Hospital